HAYWARD, Calif.--(EON: Enhanced Online News)--Moximed, Inc. announced today that the KineSpring® System, an implantable medical spring for knee osteoarthritis that works by unloading the weight on the diseased joint, has been successfully implanted in the first patients enrolled in the UK arm of its multi-centre GOAL study. This non-randomized pivotal trial is comparing the safety and effectiveness of the KineSpring System with high tibial osteotomy (HTO), a procedure used to treat the pain and discomfort associated with medial compartment knee osteoarthritis, in a minimum of 225 patients across Europe. The UK principal investigator for the study is Mr. Michael McNicholas, Consultant Trauma and Orthopaedic surgeon, Aintree University Hospital, Liverpool.
“With this in mind, the GOAL study has been designed to enable us to see how the KineSpring System compares directly to HTO, a common, but more invasive, procedure offered to medial knee osteoarthritis patients.”
“The KineSpring System is emerging as an effective treatment option in patients with early to moderate knee osteoarthritis. These patients are typically still very active and would like to remain so. This creates a significant need for a procedure that potentially delays or avoids knee replacement,” noted Mr. McNicholas. “With this in mind, the GOAL study has been designed to enable us to see how the KineSpring System compares directly to HTO, a common, but more invasive, procedure offered to medial knee osteoarthritis patients.”
The purpose of the post-market study is to demonstrate that the KineSpring System is non-inferior to HTO in the treatment of symptoms associated with osteoarthritis of the medial compartment of the knee. Participating centres in the UK include Royal Bournemouth Hospital and North Hampshire Hospital, Basingstoke, with several more to be added.
Osteoarthritis (OA), the most common form of arthritis, is a degenerative disease affecting the hands, knees, hips, feet and spine. It is caused by changes in cartilage, the soft tissue that cushions and protects bone, leading to pain and changes in the shape of the joint. In knee OA, as the cartilage wears away, the bone ends may begin to rub against each other, causing severe pain. While drugs and certain cartilage repair procedures may temporarily relieve pain, they often do not treat the underlying problems that led to OA. Conversely, research suggests that if the excess stress on the joint is removed, as with the KineSpring System, pain may decrease and the natural joint tissues may demonstrate some recovery.
About the KineSpring System
The KineSpring System is intended to provide an innovative treatment option for patients with early to moderate knee osteoarthritis that find conservative therapy, such as pain medication and knee braces, unsuccessful, but who are not ready for joint-altering knee surgery. The KineSpring System is implanted in the subcutaneous tissue alongside the joint to cushion the knee from excessive loading. Importantly, the KineSpring System is completely joint-sparing, so future treatment options are maintained.
The KineSpring System is CE marked in Europe and has been successfully implanted into nearly 500 osteoarthritis patients worldwide.
Moximed® Inc is dedicated to improving the standard of care for patients with osteoarthritis. OA, the most common form of arthritis, leads to a breakdown of the joint’s cartilage and often results in joint pain and loss of motion. OA commonly affects the knees, hips, hands, or back. Moximed is initially focused on developing minimally invasive, joint preserving solutions for patients with knee osteoarthritis. Moximed is supported by world-leading venture investors including, New Enterprise Associates (NEA), Morgenthaler Ventures, Frazier Healthcare Ventures, Gilde Healthcare Partners, GBS Venture Partners. More information can be found at www.moximed.com.